Janus kinase inhibitors ameliorate clinical symptoms in patients with STAT3 gain-of-function

被引：3

作者：

Kaneko, Shuya ^{[1
]}

Sakura, Fumiaki ^{[2
]}

Tanita, Kay ^{[1
]}

Shimbo, Asami ^{[1
]}

Nambu, Ryusuke ^{[3
]}

Yoshida, Masashi ^{[3
]}

Umetsu, Shuichiro ^{[4
]}

Inui, Ayano ^{[4
]}

Okada, Chizuru ^{[5
]}

Tsumura, Miyuki ^{[2
]}

Yamada, Mamiko ^{[6
]}

Suzuki, Hisato ^{[6
]}

Kosaki, Kenjiro ^{[6
]}

Ohara, Osamu ^{[7
]}

Shimizu, Masaki ^{[1
]}

Morio, Tomohiro ^{[1
]}

Okada, Satoshi ^{[2
]}

Kanegane, Hirokazu ^{[8
]}

机构：

[1] Tokyo Med & Dent Univ TMDU, Grad Sch Med & Dent Sci, Dept Pediat & Dev Biol, Tokyo, Japan

[2] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Pediat, Hiroshima, Japan

[3] Saitama Childrens Med Ctr, Div Gastroenterol & Hepatol, Saitama, Japan

[4] Saiseikai Yokohama Shi Tobu Hosp, Dept Pediat Hepatol & Gastroenterol, Yokohama, Kanagawa, Japan

[5] Hiroshima Chuodori Children Clin, Hiroshima, Japan

[6] Keio Univ, Sch Med, Ctr Med Genet, Tokyo, Japan

[7] Kazusa DNA Res Inst, Dept Technol Dev, Chiba, Japan

[8] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Child Hlth & Dev, 1-5-45 Yushima,Bunkyo Ku, Tokyo 1138519, Japan

来源：

IMMUNOTHERAPY ADVANCES | 2023年 / 3卷 / 01期

关键词：

signal transducer and activator of transcription 3; gain-of-function; Janus kinase inhibitor; tofacitinib; ruxolitinib; lymphoblastoid cell lines;

D O I：

10.1093/immadv/ltad027

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Germline gain-of-function (GOF) variants in the signal transducer and activator of transcription 3 (STAT3) gene is an inborn error of immunity presenting with autoimmunity and lymphoproliferation. Symptoms can vary widely, and no effective treatment has been established. This study investigated the efficacy of Janus kinase (JAK) inhibitors (JAKi) in patients with STAT3-GOF. Four patients were enrolled and their clinical symptoms before and after the initiation of treatment with JAKi were described. A cell stimulation assay was performed using Epstein-Barr virus transformed lymphoid cell lines (EBV-LCLs) that were derived from the patients with STAT3-GOF. The patients presented with various symptoms, and these symptoms mostly improved after the initiation of JAKi treatment. Upon interleukin-6 stimulation, the EBV-LCLs of patients showed enhanced STAT3 phosphorylation compared with those of the EBV-LCLs of healthy controls. In conclusion, four Japanese patients with STAT3-GOF were successfully treated with JAKi. JAKi ameliorated various symptoms and therefore, the use of JAKi could be an effective treatment option for patients with STAT3-GOF. Graphical Abstract

引用

页数：8

共 50 条

[21] Investigating the Impact of Germline STAT3 Gain-of-Function on Regulatory T Cells
Schmitt, Erica
Keppel, Molly
Saucier, Nermina
Toth, Kelsey
Vogel, Tiphanie
Vogel, Peter
Cooper, Megan
JOURNAL OF CLINICAL IMMUNOLOGY, 2021, 41 (SUPPL 1) : S10 - S10
[22] GAINING MORE INSIGHT INTO STAT3 GAIN-OF-FUNCTION DISEASE: A CASE PRESENTATION
Cherk, E.
Dimitriades, V.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2023, 131 (05) : S148 - S148
[23] Low IgE Is a Useful Tool to Identify STAT3 Gain-of-Function Mutations
Johnson, Matthew B.
Flanagan, Sarah E.
Martins, Thomas B.
Hill, Harry R.
Hattersley, Andrew T.
McDonald, Timothy J.
CLINICAL CHEMISTRY, 2016, 62 (11) : 1536 - 1538
[24] STAT3 gain-of-function mutation in a patient with pulmonary Mycobacterium abscessus infection
Gonzalez-Mancera, Miguel S.
Johnson, Britt
Mirsaeidi, Mehdi
RESPIRATORY MEDICINE CASE REPORTS, 2020, 30
[25] Gain-of-function STAT1 mutations impair STAT3 activity in patients with chronic mucocutaneous candidiasis (CMC)
Zheng, Jie
de Veerdonk, Frank L. van
Crossland, Katherine L.
Smeekens, Sanne P.
Chan, Chun M.
Al Shehri, Tariq
Abinun, Mario
Gennery, Andrew R.
Mann, Jelena
Lendrem, Dennis W.
Netea, Mihai G.
Rowan, Andrew D.
Lilic, Desa
EUROPEAN JOURNAL OF IMMUNOLOGY, 2015, 45 (10) : 2834 - 2846
[26] GAIN-OF-FUNCTION STAT1 MUTATION IMPAIRS STAT3 FUNCTION PREDISPOSING TO CHRONIC MUCOCUTANEOUS CANDIDIASIS
Zheng, Jie
de Veerdonk, Frank van
Crossland, Katherine
Smeekens, Sanne P.
Abinun, Mario
Gennery, Andrew R.
Mann, Jelena
Lendrem, Dennis
Netea, Mihai G.
Rowan, Andrew D.
Lilic, Desa
JOURNAL OF CLINICAL IMMUNOLOGY, 2014, 34 (06) : 704 - 704
[27] INHIBITION OF STAT3 IN PBMCS FROM RHEUMATOID ARTHRITIS PATIENTS: CLUES TO UNDERSTAND SELECTIVITY OF JANUS KINASE INHIBITORS
Cacciapaglia, F.
Venerito, V.
del Vescovo, S.
Stano, S.
Bizzoca, R.
Natuzzi, D.
Lacarpia, N.
Fornaro, M.
Iannone, F.
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1167 - 1168
[28] STAT3 gain-of-function is not responsible for low total IgE levels in patients with autoimmune chronic spontaneous urticaria
Sauer, Merle
Scheffel, Joerg
Frischbutter, Stefan
Mahnke, Niklas
Maurer, Marcus
Burmeister, Thomas
Krause, Karoline
Metz, Martin
FRONTIERS IN IMMUNOLOGY, 2022, 13
[29] Efficacy of Ruxolitinib Therapy in a Patient With Severe Enterocolitis Associated With a STAT3 Gain-of-Function Mutation
Parlato, Marianna
Charbit-Henrion, Fabienne
Elie, Abi Nader
Begue, Bernadette
Guegan, Nicolas
Bruneau, Julie
Khater, Sherine
Macintyre, Elizabeth
Picard, Capucine
Frederic, Rieux-Laucat
Le Bourhis, Lionel
Allez, Matthieu
Goulet, Olivier
Cellier, Christophe
Hermine, Olivier
Cerf-Bensussan, Nadine
Malamut, Georgia
GASTROENTEROLOGY, 2019, 156 (04) : 1206 - +
[30] Efficacy of tocilizumab therapy in a patient with severe pancytopenia associated with a STAT3 gain-of-function mutation
Wang, Wenjie
Liu, Luyao
Hui, Xiaoying
Wang, Ying
Ying, Wenjing
Zhou, Qinhua
Hou, Jia
Yang, Mi
Sun, Bijun
Sun, Jinqiao
Wang, Xiaochuan
BMC IMMUNOLOGY, 2021, 22 (01)

← 1 2 3 4 5 →